Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 31, Number 5—May 2025

CME ACTIVITY - Research

Nationwide Observational Case–Control Study of Risk Factors for Aerococcus Bloodstream Infections, Sweden

John WallesComments to Author , Malin Inghammar, Magnus Rasmussen, and Torgny Sunnerhagen
Author affiliation: Central Hospital Kristianstad, Kristianstad, Sweden (J. Walles); Lund University, Malmö, Sweden (J. Walles); Lund University, Lund, Sweden (J. Walles, M. Inghammar, M. Rasmussen, T. Sunnerhagen); Skåne University Hospital, Lund (J. Walles, M. Inghammar, M. Rasmussen, T. Sunnerhagen)

Main Article

Table 3

Multivariable models used in nationwide observational case–control study of risk factors for Aerococcus BSIs, Sweden, 2012–2016*

Characteristics First model
 Final model
Adjusted odds ratio (95% CI) p value Adjusted odds ratio (95% CI) p value
Previous treatment for infection,† mo
Never Referent NA Referent NA
1–3 1.77 (1.28–2.45) <0.001 1.88 (1.38–2.56) <0.001
>3–9 1.15 (0.83–1.58) 0.40 1.21 (0.89–1.65) 0.23
>9–24
1.19 (0.90–1.59)
 0.22
1.22 (0.92–1.61)
 0.16
Malignant disease, nonurologic 1.40 (1.01–1.95) 0.046 1.39 (1.00–1.93) 0.052
Structural urologic conditions‡ 2.05 (1.63–2.57) <0.001 2.15 (1.72–2.68) <0.001
Neurologic conditions
 2.74 (2.13–3.52)
 <0.001
2.89 (2.26–3.70)
 <0.001
Hospital admissions
None Referent NA Referent NA
1–2 1.80 (1.37–2.37) <0.001 1.74 (1.34–2.25) <0.001
3–5 3.56 (2.46–5.14) <0.001 3.50 (2.50–4.88) <0.001
6–10 4.30 (2.39–7.75) <0.001 4.34 (2.57–7.66) <0.001
>10
 5.99 (2.08–17.2)
 <0.001
6.81 (2.51–18.5)
 <0.001
Rheumatologic disease 0.77 (0.57–0.01) 0.061 0.77 (0.59–1.00) 0.050
Kidney disease 1.15 (0.80–1.66) 0.4 NA NA
Pulmonary conditions 1.00 (0.75–1.34) 0.98 NA NA
Gastrointestinal conditions 0.86 (0.63–1.16) 0.33 NA NA
Diabetes mellitus 0.97 (0.72–1.29) 0.81 NA NA
Cardiovascular disease 0.84 (0.65–1.08) 0.18 NA NA
No. prescribed drugs 1.03 (1.00–1.05) 0.019 NA NA
Corticosteroid therapy 0.72 (0.52–0.99) 0.040 NA NA

*First model included variables that had univariable associations with aerococcal BSI. Age, sex, and county were included in the models but were hidden because matching on those variables prevented appropriate interpretation of their respective estimates. Likelihood-ratio tests and variance inflation analyses were used to guide progressive refinement of the model. BSI, bloodstream infection; NA, not applicable. †Time in months indicates when treatment for another infection occurred before the aerococcal BSI was detected. ‡Included urological malignancies.

Main Article

Page created: March 02, 2025
Page updated: April 23, 2025
Page reviewed: April 23, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external